Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Royalty Pharma plc (RPRX)

579 + Investors. Track Smart Money conviction in RPRX. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +52
Streak
10Q ▲
Buyers last Q
58%

Smart Money Signals — RPRX

Based on 585 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 10 quarters in a row

last 6Q
For 10 consecutive quarters, more hedge funds added RPRX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
585 hedge funds hold RPRX right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +31% more funds vs a year ago

fund count last 6Q
+138 new funds entered over the past year (+31% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟡

Slight buying edge — 58% buying

340 buying245 selling
Last quarter: 340 funds bought or added vs 245 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
➡️

Steady new buyers — ~117 new funds per quarter

new funds entering per quarter
Funds opening this position for the first time: 79 → 89 → 112 → 117. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.
🔒

43% of holders stayed for 2+ years

■ 43% conviction (2yr+) ■ 27% medium ■ 29% new
254 out of 585 hedge funds have held RPRX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💰

Value +22% but shares only +0% — price-driven

Value
+21%
Shares
+0%
Last quarter: the total dollar value of institutional holdings rose +22%, but actual share count only changed +0%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
📈

Growing discovery — still being found

93 → 79 → 89 → 112 → 117 new funds/Q
New funds entering each quarter: 79 → 89 → 112 → 117. A growing number of institutions are discovering RPRX each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.
🏛️

Veteran-anchored — 50% veterans vs 37% newcomers

■ 50% veterans ■ 13% 1-2yr ■ 37% new
Entry-cohort mix of 593 holders: 295 (50%) are 2+ year veterans, 80 entered 1–2 years ago, and 218 (37%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
🏆

Elite ownership — 61% AUM from top-100 funds

61% from top-100 AUM funds
61 of 582 holders are among the 100 largest funds by AUM, controlling 61% of total institutional value in RPRX. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
4.2
out of 10
Moderate Exit Risk
Exit risk score 4.2/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — RPRX

In 2026 Q1, 340 hedge funds were net buyers of RPRX (117 opened a new position, 223 added to an existing one), while 245 reduced or exited (180 trimmed, 65 sold completely) — a 58% buyer ratio, indicating a slight buying edge. This marks 10 consecutive quarters of net institutional buying — a persistent conviction signal. 61% of total institutional value in RPRX is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: +52 funds (more new holders than closures). Total institutional holders: 585.

Hedge Fund Ownership: RPRX

How many hedge funds hold RPRX — quarterly history vs. share price
Quarterly hedge fund ownership of RPRX vs. share price

Market Analysis: RPRX

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: RPRX

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Royalty Pharma plc (RPRX) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much RPRX has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 81d ago
RPRX
nan%
XLV
+2.1%

RPRX outperformed XLV by nan% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 36d ago
RPRX
nan%
XLV
+3.2%

Since the filing became public, RPRX outperformed XLV by nan% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Strong Institutional Conviction

Multiple high-quality funds hold meaningful positions with strong conviction.

48 top-rated funds 8 high-conviction
Consensus
7.3
/ 10
breadth
×
Elite
6.0
/ 10
conviction
Hedge Fund Positioning: RPRX
579 + Investors

Track Smart Money conviction in RPRX. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 579 533 8.63%
13F Shares 356M 356M -0.18%
Total Value $16.60B $13.66B 21.51%
New Positions 113 112 +1
Increased Positions 219 227 -8
Closed Positions 67 57 +10
Reduced Positions 178 134 +44
Total Calls 6 4 50.0%
Total Puts 3 3 -
PUT/CALL Ratio 0.5 0.75 Bullish

Statistics: RPRX

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

579 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in RPRX. Verified SEC 13F-HR filings.

QUARTER:
Top 25 RPRX holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Caledonia (Private) Investments Pty Ltd 10.00% 7,168,399 $343.9M
2 Dorsey Asset Management, LLC 8.70% 2,276,570 $109.2M
3 Regal Partners Ltd 6.84% 2,624,472 $125.9M
4 Davern Capital Partners, LP 6.84% 520,009 $24.9M
5 Patient Capital Management, LLC 6.39% 3,643,716 $174.8M
6 Lion Point Capital, LP 6.14% 21,400 $1.0M
7 New South Capital Management Inc 6.04% 2,625,863 $126.0M
8 CM Management, LLC 5.01% 125,000 $6.0M
9 Torray Investment Partners LLC 4.54% 645,425 $31.0M
10 Cooper Investors Pty Ltd 4.14% 211,821 $10.2M
11 Inlet Private Wealth, LLC 2.65% 216,000 $10.4M
12 Homestead Advisers Corp 2.12% 1,653,042 $78.9M
13 Kirr Marbach & Co LLC /In/ 2.08% 237,895 $11.4M
14 Goodman Advisory Group, LLC 2.07% 166,598 $8.0M
15 Punch & Associates Investment Management, INC. 1.66% 598,617 $28.7M
16 Kearns & Associates LLC 1.50% 58,240 $2.8M
17 Rhenman & Partners Asset Management AB 1.38% 233,000 $11.2M
18 Taproot Management LP 1.17% 129,592 $6.2M
19 Monetta Financial Services Inc 1.12% 30,000 $1.4M
20 Brasada Capital Management, LP 1.05% 121,499 $5.7M
21 Eventide Asset Management, LLC 1.04% 1,312,534 $62.6M
22 Capital Group Investment Management Pte. Ltd. 1.02% 124,024 $5.9M
23 Capital International Ltd /Ca/ 1.01% 570,577 $27.4M
24 Aurora Investment Counsel 0.94% 35,415 $1.7M
25 Hosking Partners LLP 0.86% 498,037 $23.9M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Royalty Pharma plc (RPRX)

What does the Smart Money Trend signal show for RPRX?

Buying streak — 10 quarters in a row: For 10 consecutive quarters, more hedge funds added RPRX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for RPRX?

Slight buying edge — 58% buying: Last quarter: 340 funds bought or added vs 245 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for RPRX holders?

Elite ownership — 61% AUM from top-100 funds: 61 of 582 holders are among the 100 largest funds by AUM, controlling 61% of total institutional value in RPRX. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held RPRX?

43% of holders stayed for 2+ years: 254 out of 585 hedge funds have held RPRX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Royalty Pharma plc (RPRX) following the 2026 Q1 hedge fund 13F filings?

As of today, RPRX has moved nan% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.2% for the XLV sector ETF — an outperformance of nan%. Since the quarter end (March 31, 2026), RPRX has gained nan% vs +2.1% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →